Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

A large study of 133,764 adults found that a voluntary digital lifestyle program reduced 10-year diabetes risk by 45.6% in prediabetics and doubled remission rates in diabetics, with significant ...

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...

A study published in the British Medical Journal investigated the relationship between baseline low-density lipoprotein cholesterol (LDL-C) levels and the | Immunology ...

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...